- 2 hrs ago Daily Horoscope, 24 May 2022: Check Today's Horoscope Predictions For All Zodiac Signs
- 17 hrs ago What Are Empty Calories? Major Sources, Disadvantages And How To Replace Them
- 18 hrs ago Omicron Subvariants BA.4 And BA.5 In India: What You Need To Know
- 19 hrs ago First Death Of A Child Reported In Mexico Due To Mysterious Severe Hepatitis: Things To Know
- News US President Biden welcomes PM Modi at Quad Summit, says it’s wonderful to see you again in person
- Movies Sarkaru Vaari Paata Day 12 Box Office Collection: Mahesh Babu's Film Slows Down At The Box Office
- Sports Racing Along The Singalong Track in Chennai
- Travel GlampEco - Glamping At India's First Geodesic Dome Stay
- Finance Motilal Oswal Suggests Buy This Stock For 25% Potential Gains, Declared Final Dividend Of Rs 6.25
- Education NABARD AM Prelims Mains 2021 Cut Off Marks, Check NABARD Assistant Manager RDBS Rajbhasha Cut Off Details Here
- Automobiles KTM RC 390 Launched At Rs 3.14 Lakhs
- Technology Vivo T2 5G Launch Postponed; Check New Launch Date, Features & Expected Pricing
Neuralink, co-founded by Elon Musk, is the first neurotechnology company to develop implantable brain-machine interfaces (BMIs), a technology that can help study, treat and prevent neurological disorders.
As per recent news reports, Synchron, owned by Thomas J. Oxley, has also developed a brain-computer interface that competes with Musk's Neuralink. The company has already enrolled six severely paralysed patients for human testing in the United States. The interface will enable the patients to control digital gadgets using only their thoughts.
- wellnessSpain Set To Become The First Western Nation To Provide Three Days Of Menstrual Leave In A Month
What's Syncron New Brain Implant?
Synchron has created an endovascular brain-computer interface that uses the brain's natural path, the blood vessels, to reach every corner. The technology helps access untouched areas of the brain through blood vessels and helps in diagnosing and treating neurological diseases like Parkinson's.
The brain implant combines and advances three current research areas: neuromodulation, neuroprosthetics and neurodiagnostics.
How Does It Work?
Synchron's brain-computer interface aims to enable paralysed individuals to use computers and phones only through their brain processes.
Synchron has named the device Stentrode. In a statement, Syncron has stated that Stentrode is of a size of a paper clip and is implanted into the brain's motor cortex through the jugular vein in a minimally invasive operation.
It transforms brain activity into a standardised digital language, allowing patients to accomplish ordinary tasks such as texting, online shopping, emailing and accessing telehealth services without having to use their hands.
More On Stentrode
This is the first time the device will be tested in the United States. As per news reports, four Australian patients have already had the gadget implanted and tested. When it was proved to be safe, the trial was suggested to be made on other patients.
The new trials are "a big milestone for those living with paralysis," according to Thomas J. Oxley, CEO and founder of Synchron, who is also a neuro interventionist at Mount Sinai Hospital in New York City.
Oxley adds that Stentrode is supplied through a patient's vein until it reaches the brain, rather than drilling through the skull.
The device expands to line the walls of the blood vessels. It consists of a net-like material with 16 sensors attached. The interface is connected to a chest-mounted electronic device that converts brain signals from the motor cortex, the region of the brain that generates movement signals, into orders for a laptop computer.
Synchron is the only company that has received Food and Drug Administration (FDA) authorisation to conduct clinical studies of a permanently implantable brain-computer interface (BCI).
What To Expect?
The Stentrode brain implant, if found to be effective, might be commercialised as a device to help paralysis patients restore their freedom and quality of life.
Command, the company's new clinical trial, is being conducted under the FDA's first investigational device exemption (IDE) which allows the device in a clinical trial to gather data on its safety and effectiveness.
"The Command study progresses Synchron's technology development through the feasibility stage as we prepare for our pivotal trial," added Oxley.
- disorders cureWhat Is Cerebral Aneurysm? Causes, Symptoms, Risk Factors, Diagnosis And Treatments
- wellness10 Herbs And Spices That May Help Reduce The Risk Of Dementia
- wellnessNovel Brain Fear Mechanisms Discovered, Offers Target For Anxiety-Reducing Drugs; Study
- disorders cureWhat Is Anomic Aphasia, A Speech Problem Causing Trouble In Naming Objects? Causes, Symptoms And Treatments
- disorders cureNational Epilepsy Day 2021: What Is Status Epilepticus? Causes, Symptoms, Diagnosis And Treatments
- disorders cureWhat Is Havana Syndrome? Causes, Symptoms And Treatments
- nutrition10 Amazing Health Benefits Of Red Bananas
- healthIschemic Stroke Patient Saved By Combination Of Three Complicated Medical Procedures
- wellness20 Home Remedies To Treat Nerve Weakness, According To Experts
- disorders cureWorld Alzheimer’s Day 2021: Everything You Need To Know About Alzheimer's Disease
- wellnessCan Coronavirus Cause Damage to The Central Nervous System?
- wellnessBrain And Exercise: 9 Ways In Which Exercise Benefits Our Brain